Help us help you: Longevity biotech survey

A new survey on translational processes and hurdles to clinical trials in Longevity biotech.

We’re working with two MDs: Oliver Zolman and Jian Fransen, on a confidential 10-minute survey to help identify the barriers that innovators are facing in bringing Longevity biotech innovations to market.

We will, of course, be sharing the top-level results and we hope the survey will help identify which of the four key innovation risk areas that aging biotech is most exposed to:

1) Demand
2) Execution
3) Cashflow
4) Technology

Following the 10-minute survey, and only as a value-add option, Oliver and Jian are offering a confidential follow-up call to help analyse your answers and craft a personalised risk profile for your business.

This risk profile is a free confidential systematic assessment of your innovation, designed to help you decide how to reduce the risk of your innovation failing to reach the market.

Thanks in advance to our respondents!

Phil Newman
Editor-in-Chief Phil is Editor-in-Chief Longevity.Technology and founder of Crowd Longevity a digital investment platform for international investors and Longevity start-ups launching in 2020.

In his career, Phil has held c-level management positions; applying his marketing and business development expertise into these tech sectors: Longevity; IoT; AI; Medical Devices; Biopharma; 3D Manufacturing; Smartgrid and Sustainability.

Latest articles

AI app reveals your biological age – and how to slow it down

Only as old as you feel ... or only as old as your Young.AI app tells you? We use our phones for just about everything...

Psychobiome: trusting your gut for Longevity

Scientists studying how the microbiome affects our mood aim to develop gut microbiome-modulating formulations to treat depression and other brain diseases. Recent work from Katya...

Startup Showcase: Jinfiniti: What do you think?

Comprehensive biomarker tech: Invest, buy, or both? It's time to have your say on Jinfiniti. We like what Jinfiniti are doing; but that's just our...

When AI means artificial immortality: just ask Alexa

Hereafter is turning dead ends into conversational opportunities. Understandably, we use Longevity in a mostly physical sense - extending lifespan and healthspan and combating aging...